Beyond Hormones: Landmark Science Review Reveals How X and Y Chromosomes Direct Cellular Aging, Immunity, and Disease Risk.

A comprehensive review published in Science synthesizes decades of genomic, clinical, and preclinical data to demonstrate that sex chromosomes exert a direct, cell-autonomous influence on human health, longevity, and disease progression far beyond their traditional role in biological sex determination. Co-led by researchers from the University of Arizona Cancer Center and the University of California, San Francisco, the study establishes that intrinsic genetic mechanisms on the X and Y chromosomes—including X-chromosome inactivation escape, parental imprinting, and mosaic chromosome loss—shape immune responses, cardiometabolic function, neurodegeneration, and oncology independent of circulating sex hormones like estrogen and testosterone. The findings challenge long-standing biomedical paradigms and present a compelling case for integrating sex-aware genomic profiling into clinical trial design, biomarker discovery, and personalized therapeutic interventions.

TUCSON, Ariz. — For decades, physiological differences in disease prevalence, immune response, and therapeutic efficacy between biological males and females were attributed almost exclusively to circulating sex hormones. Endocrine signaling pathways governed by estrogen, progesterone, and testosterone served as the primary explanatory model for sex-based disparities in conditions ranging from autoimmune disorders to cardiovascular disease.

However, a landmark synthesis of genomic, clinical, and translational research published in the journal Science demonstrates that the X and Y sex chromosomes themselves actively drive cellular function, tissue aging, and pathology throughout the human lifespan.

Co-led by Dr. Dan Theodorescu, a physician-scientist and director of the University of Arizona Cancer Center, and Dr. Dena B. Dubal, a professor of neurology at the University of California, San Francisco (UCSF), the comprehensive review brings together findings from human cohort studies, transgenic mouse models, and single-cell genomic technologies. The study establishes that intrinsic sex chromosome biology operates parallel to, and frequently interacts with, hormonal pathways to govern fundamental cellular processes across key organ systems.

The Architecture of Sex Chromosome Gene Dosage

Biological females typically possess two X chromosomes ($XX$), while biological males carry one X and one Y chromosome ($XY$). To prevent a double dose of gene expression in females, embryonic development initiates a process known as X-chromosome inactivation (XCI), in which one X chromosome in every female cell is silenced and condensed into a heterochromatic Barr body.

However, genomic research evaluated in the Science review reveals that X-inactivation is incomplete. Between 15% and 23% of genes on the silenced female X chromosome regularly escape inactivation, remaining transcriptionally active and granting female cells a higher dosage of specific proteins involved in RNA processing, chromatin remodeling, and immune signaling. Furthermore, as tissues age, additional genes on the silenced X chromosome can reactivate, altering cellular function over time.

In addition to gene dosage, parental origin—known as genomic imprinting—plays a significant role in cellular outcomes. While males inherit their single X chromosome exclusively from their mother, female cells randomly select either the maternal ($X_m$) or paternal ($X_p$) X chromosome for active use. In rodent models evaluated in the review, brain cells that predominantly expressed the maternal X chromosome exhibited accelerated neuro-aging, heightened inflammatory markers, and faster cognitive decline compared to those utilizing the paternal X.

Mosaic Chromosome Loss: Biomarkers of Aging and Vulnerability

As human tissues age, errors in cell division can result in the loss of an entire sex chromosome—a phenomenon termed mosaic loss. In men, the loss of the Y chromosome (LOY) in circulating blood cells is one of the most common acquired somatic mutations, detected in a significant percentage of aging males. In women, mosaic loss of an X chromosome (LOX) occurs with increasing frequency past the fifth decade of life.

Historically dismissed as benign byproducts of aging, these chromosomal losses are now understood to be active participants in disease development:

• Loss of Y (LOY) in Males: Measured primarily in peripheral blood leukocytes, LOY is strongly correlated with increased overall mortality, aggressive non-hematologic cancers, cardiac fibrosis, severe infectious disease outcomes, and Alzheimer’s disease.
• Loss of X (LOX) in Females: Though less thoroughly mapped than LOY, age-related LOX in hematological lineages is clinically linked to elevated risks for acute leukemias and specific autoimmune dysfunctions.

Oncology and Immune Evasion: The Y Chromosome’s Role in Cancer

Dr. Theodorescu’s laboratory at the University of Arizona Cancer Center has led pioneering research into the functional consequences of LOY in oncology. His team discovered that when male T cells or tumor cells lose their Y chromosome, the structural loss alters normal gene expression pathways required for immune detection.

“When we look inside human cells, we see that X and Y chromosomes are participants in health and disease throughout a person’s life,” Dr. Theodorescu noted during a interview regarding the review’s publication. “In cancer, for example, our laboratory has found that tumors that lose the Y chromosome can evade the immune system, yet may respond better to immune checkpoint inhibitor therapies. Understanding this biology could help us tailor treatment.”

Theodorescu’s prior studies demonstrated that LOY in normal-appearing tissues can serve as an early warning signal, marking hidden zones of genetic instability before clinically detectable tumors form. These findings explain why LOY has historically been associated with increased carcinoma mortality in men, while simultaneously offering a concrete target for precision therapy.

Translational Potential and Clinical Trial Reform

The synthesis originated from expert working sessions at the 2025 National Institute on Aging (NIA) Workshop, Sex Differences Impacting Human Health Across the Lifespan, organized in collaboration with Dr. Francesca Duncan of the Northwestern University Feinberg School of Medicine. Additional co-authors include Dr. Fabrisia Ambrosio of the Schoen Adams Research Institute at Harvard Medical School and Dr. Michael B. Stout of the Oklahoma Medical Research Foundation.

The authors emphasize that historical clinical trials have frequently failed to disaggregate data by sex or account for sex chromosome mosaicism, potentially obscuring therapeutic efficacy or toxicities unique to $XX$ or $XY$ cellular environments.

“Our hope is that this review will stimulate further investigation and bring greater awareness to the significant potential of studying the X and Y chromosomes in cancer and other diseases, with far-reaching diagnostic and therapeutic implications,” Dr. Theodorescu stated. “This would help ensure that treatments and diagnostics are tailored to match every patient’s unique profile. When clinical trials are designed to be sex-aware, researchers can turn these cellular differences into personalized medical care.”

As precision medicine advances, integrating sex chromosome biology into standard diagnostic algorithms promises to redefine therapeutic stratification across oncology, cardiology, neurology, and immunology.